Sorrento Therapeutics (SRNE) Trading Down 5.6%
Sorrento Therapeutics Inc (NASDAQ:SRNE) traded down 5.6% on Wednesday . The stock traded as low as $2.20 and last traded at $2.20. 873,756 shares were traded during mid-day trading, an increase of 5% from the average session volume of 830,961 shares. The stock had previously closed at $2.33.
Several equities research analysts have recently weighed in on the company. Oppenheimer set a $7.00 price objective on Sorrento Therapeutics and gave the company a “buy” rating in a research report on Tuesday, August 22nd. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 target price on shares of Sorrento Therapeutics in a research report on Monday, September 18th. Six analysts have rated the stock with a buy rating, The stock has a consensus rating of “Buy” and a consensus price target of $11.50.
The company has a debt-to-equity ratio of 0.18, a current ratio of 0.54 and a quick ratio of 0.54.
About Sorrento Therapeutics
Sorrento Therapeutics, Inc is a biopharmaceutical company. The Company is engaged in the discovery, acquisition, development and commercialization of drug therapeutics. Its primary therapeutic focus is oncology, including the treatment of chronic cancer pain. It is also developing therapeutic products for other indications, including immunology and infectious diseases.
Receive News & Stock Ratings for Sorrento Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sorrento Therapeutics Inc and related stocks with our FREE daily email newsletter.